Dr. Thomas M. Wilcox, DO
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 432
Licensed in Colorado since 1996, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
CO license DR.0035574 (first issued 1996; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boulder Community Health Boulder, CO
Medical groups
- Boulder Community Health (264 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 432
- Services billed
- 1,259
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 440 | 256 |
| Test to examine how well the lungs exchange gases | 145 | 142 |
| Test to determine lung volumes using gas dilution or washout | 139 | 136 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 108 | 56 |
| Test to measure expiratory airflow and volume | 82 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 81 | 81 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 77 | 75 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 39 | 39 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 27 | 14 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boulder, CO | 511 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Boulder, CO | 402 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Boulder, CO | 246 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boulder, CO | 207 |
| Montelukast Sodium Other prescribers in Boulder, CO | 125 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Boulder, CO | 115 |
| Prednisone Other prescribers in Boulder, CO | 69 |
| Azithromycin Other prescribers in Boulder, CO | 59 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Boulder, CO | 56 |
| Advair Hfa (fluticasone propion/salmeterol) Other prescribers in Boulder, CO | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $72.34 in total to this clinician.
| Lilly USA, LLC | $30.74 |
|---|---|
| Avadel Cns Pharmaceuticals, LLC | $24.70 |
| Resmed Corp | $16.90 |
| Food and Beverage | $72.34 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $163,649 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.